GLP-1 Market
LLY $1283.66 ▲ +3.5% NVO $39.35 ▲ +2.4% PFE $30.11 ▲ +2.3% VKTX $26.71 ▲ +6.6% KLRA $12.89 ▲ +12.8% GPCR $22.88 ▲ +4.0% RHHBY $59.11 ▲ +3.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Bempedoic Acid + Ezetimibe

Company
Bahria University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 21, 2026

Find a Clinical Trial Near Me

See recruiting studies for Bempedoic Acid + Ezetimibe and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05103254

    Bempedoic Acid Pregnancy Surveillance Program

    Esperion Therapeutics, Inc. 20 participants Est. completion 2032-05 1 site
    Other conditions: Pregnancy, Hyperlipidemias
    View official trial listing →
  • Recruiting NCT NCT07206472

    A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia

    Daiichi Sankyo 2120 participants Est. completion 2028-12-31 38 sites
    Other conditions: Primary Hypercholesterolaemia, Mixed Dyslipidemia
    View official trial listing →
  • Recruiting NCT NCT07824323

    Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome

    Not yet reported Taipei Medical University Hospital 400 participants Est. completion 2028-12 1 site
    Other conditions: Acute Coronary Syndromes, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT03337308

    A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

    Not yet reported Esperion Therapeutics, Inc. 382 participants Est. completion 2018-07-18 5 sites Stand-alone
    Other conditions: Hyperlipidemias
    View official trial listing →
  • Completed NCT NCT03531905

    Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

    Not yet reported Esperion Therapeutics, Inc. 242 participants Est. completion 2019-06-18 4 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes, Cholesterolemia
    View official trial listing →
  • Status unknown NCT NCT05263778

    Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

    Not yet reported Kaiser Permanente 500 participants Est. completion 2023-12 1 site
    Cardiovascular disease Other conditions: NSTEMI, STEMI
    View official trial listing →
  • Completed NCT NCT06021951

    Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

    Not yet reported Esperion Therapeutics, Inc. 16 participants Est. completion 2024-03-22 1 site
    Other conditions: Healthy Lactating Women
    View official trial listing →
  • Withdrawn NCT NCT06280976

    Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

    Not yet reported University of Louisville Est. completion 2025-01-01 1 site
    Cardiovascular disease Other conditions: Atherosclerosis, Heart Attack
    View official trial listing →
  • Status unknown NCT NCT06381947

    Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients

    Not yet reported University of Salerno 130 participants Est. completion 2025-06-30
    Cardiovascular disease Other conditions: Dyslipidemias, Statin Adverse Reaction, Lipid Metabolism Disorders
    View official trial listing →
  • Completed NCT NCT06742853

    A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

    Not yet reported AstraZeneca 81 participants Est. completion 2025-10-29 3 sites
    Other conditions: Dyslipidemia
    View official trial listing →
  • Completed NCT NCT07182383

    Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Rosuvastatin

    Not yet reported Daiichi Sankyo 58 participants Est. completion 2025-11-24 1 site
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT07201545

    Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin

    Not yet reported Daiichi Sankyo 58 participants Est. completion 2025-12-10 1 site
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT07235189

    A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin

    Not yet reported Daiichi Sankyo 58 participants Est. completion 2026-01-28 1 site
    Other conditions: Healthy Subjects
    View official trial listing →
  • Completed NCT NCT07255820

    Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol

    Not yet reported Bahria University 126 participants Est. completion 2026-06-30 1 site
    Type 2 diabetes Other conditions: Hypercholesterolemia / Elevated LDL Cholesterol
    View official trial listing →
  • Completed NCT NCT07268625

    Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin

    Not yet reported Daiichi Sankyo 58 participants Est. completion 2026-02-24 1 site
    Other conditions: Healthy Subjects
    View official trial listing →
  • Not yet recruiting NCT NCT07474649

    A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

    Not yet reported Daiichi Sankyo 103 participants Est. completion 2028-10-02 12 sites
    Other conditions: Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.